1. Home
  2. XLO vs KNRX Comparison

XLO vs KNRX Comparison

Compare XLO & KNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XLO
  • KNRX
  • Stock Information
  • Founded
  • XLO 2016
  • KNRX 2009
  • Country
  • XLO United States
  • KNRX Singapore
  • Employees
  • XLO N/A
  • KNRX N/A
  • Industry
  • XLO Biotechnology: Pharmaceutical Preparations
  • KNRX Computer Software: Programming Data Processing
  • Sector
  • XLO Health Care
  • KNRX Technology
  • Exchange
  • XLO Nasdaq
  • KNRX Nasdaq
  • Market Cap
  • XLO 41.8M
  • KNRX 49.9M
  • IPO Year
  • XLO 2021
  • KNRX 2025
  • Fundamental
  • Price
  • XLO $0.75
  • KNRX $1.90
  • Analyst Decision
  • XLO Buy
  • KNRX
  • Analyst Count
  • XLO 1
  • KNRX 0
  • Target Price
  • XLO $2.00
  • KNRX N/A
  • AVG Volume (30 Days)
  • XLO 996.7K
  • KNRX 33.4K
  • Earning Date
  • XLO 11-13-2025
  • KNRX 06-12-2026
  • Dividend Yield
  • XLO N/A
  • KNRX N/A
  • EPS Growth
  • XLO N/A
  • KNRX N/A
  • EPS
  • XLO N/A
  • KNRX N/A
  • Revenue
  • XLO $31,804,000.00
  • KNRX $10,820,365.00
  • Revenue This Year
  • XLO $519.70
  • KNRX N/A
  • Revenue Next Year
  • XLO $44.57
  • KNRX N/A
  • P/E Ratio
  • XLO N/A
  • KNRX N/A
  • Revenue Growth
  • XLO 588.40
  • KNRX 24.00
  • 52 Week Low
  • XLO $0.62
  • KNRX $1.25
  • 52 Week High
  • XLO $1.70
  • KNRX $4.00
  • Technical
  • Relative Strength Index (RSI)
  • XLO 46.63
  • KNRX N/A
  • Support Level
  • XLO $0.73
  • KNRX N/A
  • Resistance Level
  • XLO $0.81
  • KNRX N/A
  • Average True Range (ATR)
  • XLO 0.06
  • KNRX 0.00
  • MACD
  • XLO -0.00
  • KNRX 0.00
  • Stochastic Oscillator
  • XLO 51.26
  • KNRX 0.00

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.

About KNRX KNOREX LTD. Class A Ordinary Shares

Knorex Ltd is a B2B technology company providing programmatic advertising products and solutions to marketers to streamline and automate their advertising and marketing workflows. Its software offers marketers cost-effective solutions and productivity-enhancing capabilities to target audience across various advertising channels and devices through automated processes and algorithms, which is known as programmatic advertising. Its product, Knorex XPOSM, is a self-service enterprise-grade cloud platform with a suite of advertising management and execution (AMX) applications. The Company operates in one operating segment, which focuses on platform subscription fee, platform services, managed activations, and professional services.

Share on Social Networks: